50
Participants
Start Date
April 23, 2021
Primary Completion Date
March 5, 2025
Study Completion Date
March 5, 2025
Atezolizumab
Atezolizumab 1200 mg will be administered by intravenous (IV) infusion on Day 1 of each 21-day cycle.
Tiragolumab
Tiragolumab 600 mg will be administered by IV infusion on Day 1 of each 21-day cycle.
Carboplatin
Carboplatin at initial target area under the concentration curve (AUC) of 5 or 6 mg/mL/min will be administered by IV infusion on Day 1 of each 21-day cycle.
Cisplatin
Cisplatin at 75 mg/m\^2 will be administered by IV infusion on Day 1 of each 21-day cycle.
Pemetrexed
Pemetrexed at 500 mg/m\^2 will be administered by IV infusion on Day 1 of each 21-day cycle.
Gemcitabine
Gemcitabine at 1000 or 1250 mg/m\^2 will be administered by IV infusion on Days 1 and 8 of each 21-day cycle.
Paclitaxel
Paclitaxel at 175 or 200 mg/m\^2 will be administered by IV infusion on Day 1 of each 21-day cycle.
Peter Maccallum Cancer Institute, Melbourne
Sunshine Coast University Hospital, Birtinya
Kantonsspital Baden, Baden
Kantonsspital Graubünden Medizin Onkologie, Chur
UniversitätsSpital Zürich, Zurich
Kantonsspital Winterthur, Winterthur
Kantonsspital St. Gallen, Sankt Gallen
NYU Cancer Center, New York
Winthrop Univ Hospital, Mineola
Complejo Hospitalario Universitario A Coruña (CHUAC), A Coruña
St. Vincent's Hospital, Gyeonggi-do
Hospital Universitario 12 de Octubre, Madrid
Hospital Universitario Puerta de Hierro, Majadahonda
Washington University School of Medicine, St Louis
University of Southern California, Los Angeles
City of Hope Cancer Center, Duarte
City of Hope at Irvine Lennar, Irvine
Columbia University, New York
Severance Hospital, Yonsei University Health System, Seoul
ICO L'Hospitalet, L'Hospitalet de Llobregat
Corporacio Sanitaria Parc Tauli, Sabadell
Vall d?Hebron Institute of Oncology (VHIO), Barcelona, Barcelona
Hoffmann-La Roche
INDUSTRY